Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kanwal Raghav

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
The Oncologist|February 1, 2024
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid TumorsSarina A Piha-Paul, Binghe Xu, Ecaterina E Dumbrava, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2026
Erratum: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid TumorsManish R Sharma, John Powderly, Yasutoshi Kuboki, et al.
Journal of Personalized Medicine|December 24, 2021
Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic CholangiocarcinomaBrian De, Ibrahim Abu-Gheida, Aashini Patel, et al.
Medrxiv : the Preprint Server for Health Sciences|September 25, 2023
The Clinical Significance of CEA, CA19-9, and CA125 in Management of Appendiceal AdenocarcinomaAbdelrahman Yousef, Mahmoud Yousef, Mohammad Zeineddine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2021
Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver MetastasesPreeti Kanikarla Marie, Cara Haymaker, Edwin Roger Parra, et al.
Oncology|October 7, 2020
Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma PatientsReham Abdel-Wahab, Manal M Hassan, Bhawana George, et al.
Cancer Cell|January 9, 2026
Framework for cancer evolution profiling and interception in colorectal cancer: ASCEND-CRC programSalvador Alonso, Kanwal Raghav, Van K Morris, et al.
NPJ Systems Biology and Applications|December 12, 2025
Measurable imaging-based changes in enhancement of intrahepatic cholangiocarcinoma after radiotherapy reflect physical mechanisms of responseBrian De, Prashant Dogra, Mohamed Zaid, et al.
Medrxiv : the Preprint Server for Health Sciences|September 24, 2024
Measurable imaging-based changes in enhancement of intrahepatic cholangiocarcinoma after radiotherapy reflect physical mechanisms of responseBrian De, Prashant Dogra, Mohamed Zaid, et al.
Cancer Discovery|July 15, 2021
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal MesotheliomaKanwal Raghav, Suyu Liu, Michael J Overman, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
The Oncologist|February 1, 2024
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid TumorsSarina A Piha-Paul, Binghe Xu, Ecaterina E Dumbrava, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2026
Erratum: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid TumorsManish R Sharma, John Powderly, Yasutoshi Kuboki, et al.
Journal of Personalized Medicine|December 24, 2021
Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic CholangiocarcinomaBrian De, Ibrahim Abu-Gheida, Aashini Patel, et al.
Medrxiv : the Preprint Server for Health Sciences|September 25, 2023
The Clinical Significance of CEA, CA19-9, and CA125 in Management of Appendiceal AdenocarcinomaAbdelrahman Yousef, Mahmoud Yousef, Mohammad Zeineddine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2021
Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver MetastasesPreeti Kanikarla Marie, Cara Haymaker, Edwin Roger Parra, et al.
Oncology|October 7, 2020
Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma PatientsReham Abdel-Wahab, Manal M Hassan, Bhawana George, et al.
Cancer Cell|January 9, 2026
Framework for cancer evolution profiling and interception in colorectal cancer: ASCEND-CRC programSalvador Alonso, Kanwal Raghav, Van K Morris, et al.
NPJ Systems Biology and Applications|December 12, 2025
Measurable imaging-based changes in enhancement of intrahepatic cholangiocarcinoma after radiotherapy reflect physical mechanisms of responseBrian De, Prashant Dogra, Mohamed Zaid, et al.
Medrxiv : the Preprint Server for Health Sciences|September 24, 2024
Measurable imaging-based changes in enhancement of intrahepatic cholangiocarcinoma after radiotherapy reflect physical mechanisms of responseBrian De, Prashant Dogra, Mohamed Zaid, et al.
Cancer Discovery|July 15, 2021
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal MesotheliomaKanwal Raghav, Suyu Liu, Michael J Overman, et al.
Pageof 11